Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bms-817399. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 known ✓ | P32246 | 20/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bms-817399 SCHEMBL1604249 | 1.00 | CCR1 (1.00) | CCR1NR1I2 | |
| Bms-817399 SCHEMBL18786022 | 1.00 | CCR1 (1.00) | CCR1NR1I2 | |
| SCHEMBL15428423 | 0.94 | CCR1 (0.88) | CCR1NR1I2 | |
| SCHEMBL12797593 | 0.91 | CCR1 (0.82) | CCR1NR1I2 | |
| SCHEMBL1604229 | 0.91 | CCR1 (0.82) | CCR1NR1I2 | |
| SCHEMBL12730338 | 0.91 | CCR1 (0.82) | CCR1NR1I2 | |
| SCHEMBL1604230 | 0.91 | CCR1 (0.82) | CCR1NR1I2 | |
| SCHEMBL12797592 | 0.91 | CCR1 (0.82) | CCR1NR1I2 | |
| SCHEMBL14822732 | 0.90 | CCR1 (0.82) | CCR1NR1I2 | |
| SCHEMBL1665890 | 0.89 | CCR1 (0.80) | CCR1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608403-A1 | MODULATORS AND USES THEREOF | Hadasit Medical Research Services&Development Ltd. (IL) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024251939-A2 | CCR1 MODULATORS AND METHODS OF USE | UNIVERSITÉ DE GENÈVE (CH) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024089691-A1 | MODULATORS AND USES THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD (IL) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024089691-A1 | MODULATORS AND USES THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD (IL) | 2024-05-02 | — | — | WO | disclosed |
| WO-2017070431-A1 | USE OF CCR1 ANTAGONISTS AS A TREATMENT FOR TUMORS OF THE CENTRAL NERVOUS SYSTEM | MERRITT JAMES (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170112831-A1 | USE OF CCR1 ANTAGONISTS AS A TREATMENT FOR TUMORS OF THE CENTRAL NERVOUS SYSTEM | MERRITT JAMES (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170112831-A1 | USE OF CCR1 ANTAGONISTS AS A TREATMENT FOR TUMORS OF THE CENTRAL NERVOUS SYSTEM | MERRITT JAMES (US) | 2017-04-27 | — | — | US | disclosed |
| US-9095585-B2 | Bioavailable compositions of amorphous piperidinyl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-04 | — | — | US | disclosed |
| US-9095585-B2 | Bioavailable compositions of amorphous piperidinyl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2486013-B1 | PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20130023564-A1 | PIPERIDINYL DERIVATIVE AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | US | disclosed |
| US-20130023564-A1 | PIPERIDINYL DERIVATIVE AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | US | disclosed |
| US-8299098-B2 | Piperidinyl derivative as a modulator of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299098-B2 | Piperidinyl derivative as a modulator of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2011044309-A1 | PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110082113-A1 | PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | disclosed |
| US-20110082113-A1 | PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | disclosed |
| US-20110082113-A1 | PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | disclosed |
| US-20090326010-A1 | PIPERIDINYL DERIVATIVE AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-31 | — | — | US | disclosed |
| US-20090326010-A1 | PIPERIDINYL DERIVATIVE AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082113-A1 | PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR7, CCR1, CCR2 | CCR1 2/4885NR1I2 425/4885 |
| US-20170112831-A1 | USE OF CCR1 ANTAGONISTS AS A TREATMENT FOR TUMORS OF THE CENTRAL NERVOUS SYSTEM | CCR1, CCR3, CCR4 | CCR1 1/4885NR1I2 406/4885 |
| US-20090326010-A1 | PIPERIDINYL DERIVATIVE AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | CCR2, CCR5, CCL11 | CCR1 5/4885NR1I2 275/4885 |
| US-20130023564-A1 | PIPERIDINYL DERIVATIVE AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | CCR2, CCR5, CCL11 | CCR1 5/4885NR1I2 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.